Related Experiment Video
Updated: May 21, 2026
Oral Gavage in Neonatal Mouse Pups and Functional Assessment of Gut Barrier Integrity Using Ussing Chambers
Published on: January 9, 2026
Early miglustat therapy in infantile Niemann-Pick disease type C
Maja Di Rocco1, Andrea Dardis, Annalisa Madeo
1Unit of Rare Diseases, Department of Pediatrics, Gaslini Institute, Genoa, Italy. majadirocco@ospedale-gaslini.ge.it
Insights
Early miglustat treatment may prevent neurologic symptoms in Niemann-Pick disease type C. This study suggests substrate reduction therapy is more effective when initiated before neurological signs appear in pediatric patients.
Area of Science:
- Biochemistry
- Genetics
- Pediatrics
Background:
- Niemann-Pick disease type C is a rare genetic disorder affecting cholesterol transport and causing lipid accumulation.
- Substrate reduction therapy using miglustat inhibits glycosphingolipid synthesis, showing promise in animal models of Niemann-Pick disease type C.
- Miglustat is approved in Europe for treating progressive neurological symptoms in Niemann-Pick disease type C patients.
Observation:
- This study reports on two pediatric Niemann-Pick disease type C patients receiving early miglustat therapy.
- Patient 1, diagnosed with early-infantile onset, started miglustat at 7 months old.
- Patient 2, with a family history, began treatment at 19 months old, prior to neurological symptoms.
Findings:
- After 7 and 5 years of treatment, both patients remain free of neurological manifestations.
- Early intervention with miglustat appears to prevent the onset of neurological symptoms in these cases.
- The findings suggest a potential benefit of initiating miglustat therapy before neurological disease progression.
Implications:
- Miglustat may be more effective as a preventative treatment for neurological manifestations in infantile-onset Niemann-Pick disease type C.
- Early diagnosis and treatment initiation are crucial for optimizing therapeutic outcomes.
- Further research into the preventative potential of miglustat in Niemann-Pick disease type C is warranted.
Abstract:
Niemann-Pick disease type C is a rare inherited cholesterol trafficking disorder, where impaired intracellular lipid transport leads to storage of unesterified cholesterol and glycosphingolipids in many tissues, including the brain. Substrate reduction therapy with miglustat, an iminosugar that inhibits glycosphingolipid synthesis, was proposed to treat Niemann-Pick disease type C, based on evidence of slower disease progression and prolonged survival in animal models. Miglustat was subsequently approved in Europe to treat progressive neurologic manifestations in both children and adults in early 2009, based on clinical study data. We report on the early treatment of two pediatric Niemann-Pick type C patients with miglustat. Patient 1, a 7.5-year-old girl with early-infantile onset, began receiving miglustat at age 7 months. Patient 2, the brother of a girl diagnosed with late-infantile onset Niemann-Pick type C, began receiving miglustat at age 19 months, when he was asymptomatic for neurologic disease. After 7 and 5 years of miglustat therapy, respectively, both patients remain free of neurologic manifestations. These findings suggest that miglustat may be more effective if used to prevent, rather than treat, neurologic manifestations in infantile-onset Niemann-Pick type C.
